Abstract
Approximately 50% of patients with lung adenocarcinoma (LUAD) in Asian populations harbor epidermal growth factor receptor (EGFR) mutations. Although the current front-line third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) targeted therapy can benefit these EGFR mutation-positive patients, treatments for non-small cell lung cancer (NSCLC) patients with EGFR-TKI resistance are limited. The study aimed to explore the application of both angiogenic and PD-1 blockade in NSCLC patients who had failed EGFR-TKIs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
